0JXZ Stock Overview
A biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Galapagos NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €26.20 |
| 52 Week High | €38.98 |
| 52 Week Low | €21.82 |
| Beta | 0.060 |
| 11 Month Change | -3.68% |
| 3 Month Change | -0.59% |
| 1 Year Change | -22.51% |
| 33 Year Change | -38.85% |
| 5 Year Change | -85.15% |
| Change since IPO | 309.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0JXZ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 2.2% | 2.0% | 1.7% |
| 1Y | -22.5% | -17.5% | 8.3% |
Return vs Industry: 0JXZ underperformed the UK Biotechs industry which returned -17.5% over the past year.
Return vs Market: 0JXZ underperformed the UK Market which returned 8.3% over the past year.
Price Volatility
| 0JXZ volatility | |
|---|---|
| 0JXZ Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0JXZ has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0JXZ's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 683 | Paul Stoffels | www.glpg.com |
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l.
Galapagos NV Fundamentals Summary
| 0JXZ fundamental statistics | |
|---|---|
| Market cap | €1.72b |
| Earnings (TTM) | -€60.61m |
| Revenue (TTM) | €260.09m |
6.6x
P/S Ratio-28.3x
P/E RatioIs 0JXZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0JXZ income statement (TTM) | |
|---|---|
| Revenue | €260.09m |
| Cost of Revenue | €331.48m |
| Gross Profit | -€71.38m |
| Other Expenses | -€10.77m |
| Earnings | -€60.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 12, 2025
| Earnings per share (EPS) | -0.92 |
| Gross Margin | -27.45% |
| Net Profit Margin | -23.30% |
| Debt/Equity Ratio | 0% |
How did 0JXZ perform over the long term?
See historical performance and comparison